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Abstract By analyzing human embryonic kidney 293 cell
transfectants stably overexpressing various types of phospholip-
ase A2 (PLA2), we have shown that polyunsaturated fatty acids
(PUFAs) preferentially activate type IIA secretory PLA2
(sPLA2-IIA)-mediated arachidonic acid (AA) release from
interleukin-1 (IL-1)-stimulated cells. When 293 cells prelabeled
with [3H]AA were incubated with exogenous PUFAs in the
presence of IL-1 and serum, there was a significant increase in
[3H]AA release (in the order AAs linoleic acids oleic acid),
which was augmented markedly by sPLA2-IIA and modestly by
type IV cytosolic PLA2 (cPLA2), but only minimally by type VI
Ca2+-independent PLA2, overexpression. Transfection of cPLA2
into sPLA2-IIA-expressing cells produced a synergistic increase
in IL-1-dependent [3H]AA release and subsequent prostaglandin
production. Our results support the proposal that prior produc-
tion of AA by cPLA2 in cytokine-stimulated cells destabilizes the
cellular membranes, thereby rendering them more susceptible to
subsequent hydrolysis by sPLA2-IIA.
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1. Introduction
The phospholipase A2 (PLA2) family comprises a growing
number of lipolytic enzymes that play pivotal roles in phos-
pholipid remodeling, host defense, digestion, and signal trans-
duction via the production of lipid mediators such as arach-
idonic acid (AA)-derived eicosanoids, lysophosphatidic acid
and platelet-activating factor. More than 10 PLA2 isozymes
are found in mammalian cells, and these can be subdivided
into several classes based upon their primary structures, enzy-
matic properties, subcellular distributions, and functions [1].
Cytosolic Ca2-dependent PLA2 (type IV cPLA2), which
undergoes translocation from the cytosol to the perinuclear
membrane in response to submicromolar increases in cyto-
plasmic Ca2 levels and is activated by mitogen-activated pro-
tein kinase-directed phosphorylation, is thought to be essen-
tial for lipid mediator generation in activated cells [2].
Cytosolic Ca2-independent PLA2 (type VI iPLA2) forms a
multimeric complex and is implicated mainly in the phospho-
lipid remodeling pathway [3]. The secretory PLA2 (sPLA2)
group includes ¢ve isozymes (IB, IIA, IIC, V, and X), all of
which require millimolar Ca2 for enzymatic activity in vitro
[4]. The expression of sPLA2-IIA and attendant delayed pros-
taglandin (PG) generation are often strongly induced in sev-
eral types of cell after proin£ammatory stimuli such as inter-
leukin-1 (IL-1) [5,6]. Our recent analysis using transfectants
overexpressing each PLA2 con¢rmed that cPLA2 and the two
heparin-binding sPLA2 isozymes, sPLA2-IIA and sPLA2-V,
are ‘signaling’ PLA2s that contribute to PG biosynthesis via
either of the cyclooxygenase (COX) isozymes, COX-1 or
COX-2, depending upon the phase of cell activation, while
iPLA2 is involved in phospholipid remodeling rather than
PG generation [7^9]. sPLA2-IIA and sPLA2-V, which are
functionally redundant, are capable of augmenting IL-1-
stimulated AA metabolism via the transcellular route, a prop-
erty not shared by intracellular cPLA2 [9]. However, the way
in which AA metabolism is regulated by particular sPLA2
isoforms remains obscure.
The observation that AA release by sPLA2-IIA generally
occurs in agonist-stimulated, but not quiescent, cells suggests
that membrane perturbation during cell activation is a crucial
event leading to sPLA2-mediated membrane phospholipid hy-
drolysis [10]. Several previous studies have shown that poly-
unsaturated fatty acids (PUFAs) or their oxidative products
contribute to enhanced sPLA2-IIA-mediated membrane hy-
drolysis [11^13]. However, results obtained from in vitro stud-
ies often vary according to the assay methods employed, and
may not always re£ect events occurring in vivo. In addition,
the utilization of relatively non-speci¢c PLA2 inhibitors in
these previous studies may limit generalizations based on in-
terpretation of their data.
To verify whether PUFAs do indeed a¡ect the functions of
PLA2s in mammalian cells, we utilized HEK293 cell trans-
fectants overexpressing each cPLA2 isozyme [8,9]. Here we
provide unequivocal evidence that PUFAs, AA in particular,
activate AA release mediated by sPLA2-IIA in preference to
cPLA2 and iPLA2 in IL-1-stimulated HEK293 transfectants.
Our observations appear to be in line with the hypothesis
proposed by Balsinde et al. [14,15] that prior activation of
cPLA2 is required for the adequate functioning of sPLA2 in
activated cells.
2. Materials and methods
2.1. Materials
AA, PGE2, 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and
methyl arachidonyl£uorophosphate (MAFP) were purchased from
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Cayman Chemical. Stearic acid, oleic acid and linoleic acid were ob-
tained from Sigma. Human IL-1L was purchased from Genzyme.
2.2. Cell culture
HEK293 cells were obtained from Health Science Research Resour-
ces Bank and maintained in RPMI 1640 medium (Nissui Pharmaceut-
ical) supplemented with 10% fetal calf serum (FCS). Transformants of
293 cells that stably expressed cPLA2, sPLA2-IIA and its mutant
G30S, and iPLA2 were established as described previously [8,9]. For
the co-transfection experiments, a 293 transformant expressing
sPLA2-IIA was subjected to a second transfection with cPLA2, which
had previously been subcloned into pCDNA3.1/Zeo(+) (Invitrogen),
using Lipofectamine Plus reagent (Life Technologies). The cells were
then seeded into 96-well plates and cloned by culture in the presence
of 50 Wg/ml zeocin (Invitrogen) in order to establish stable transform-
ants overexpressing both PLA2s. The expression of each enzyme was
con¢rmed by RNA blotting.
2.3. RNA blotting
Approximately equal amounts (V10 Wg) of the total RNAs ob-
tained from the transfected cells were applied to individual lanes on
1.2% (w/v) formaldehyde-agarose gels, electrophoresed, and trans-
ferred to Immobilon-N membranes (Millipore). The resulting blots
were then probed with their respective cDNA probes, which had
been labeled with [32P]dCTP (Amersham) by random priming (Takara
Shuzo). All hybridizations were carried out as described previously
[7,8].
2.4. Cell activation
Cells (5U104 in 1 ml of culture medium) were seeded into individ-
ual wells on 24-well plates. In order to assess AA release, 0.1 WCi/ml
[3H]AA (Amersham) was added to the cells in each well on day 3,
when they had nearly reached con£uence, and culture was continued
for another day. After three washes with fresh medium, 250 Wl of
RPMI 1640 with or without 1 ng/ml IL-1L and 10% FCS was added
to each well and the [3H]AA released into the supernatant during
culture was measured. The percentage release of [3H]AA was calcu-
lated using the formula [S/(S+P)]U100, where S and P are the radio-
activities measured in equal portions of the supernatant and cell pel-
let, respectively. This procedure is described in detail in our previous
reports [8,9].
3. Results
3.1. Exogenous PUFAs preferentially activate sPLA2-IIA-
mediated AA release
In the present study, we used HEK293 cell stable transfec-
tants that expressed sPLA2-IIA, cPLA2 and iPLA2, and con-
¢rmed their expression by Northern and/or Western blotting
[8,9]. Parental 293 cells expressed only a trace of cPLA2, and
sPLA2 and iPLA2 were undetectable (see Fig. 4A) [8,9]. When
293 transfectants expressing sPLA2-IIA or cPLA2 were prela-
beled with [3H]AA and cultured for 4 h with IL-1 in the
culture medium, there was a marked increase in [3H]AA re-
lease, reaching 4^5%, from both transfectants, whereas release
from replicate parental cells increased only minimally (Fig.
1A). These results con¢rmed our previous ¢ndings that both
sPLA2-IIA and cPLA2 are capable of mediating IL-1/FCS-
induced delayed AA metabolism [7^9]. We found that when
AA was added exogenously to the control cells, IL-1/FCS-
dependent, but not basal, release of endogenous [3H]AA
was signi¢cantly augmented (Fig. 1A). Furthermore, IL-1/
FCS-dependent [3H]AA release by sPLA2-IIA-expressing cells
was dramatically increased by exogenous AA, reaching nearly
20% release. The catalytically inactive sPLA2-IIA mutant
G30S [8] did not elicit enhanced [3H]AA release by exogenous
AA (data not shown), implying that the enzymatic activity of
sPLA2-IIA is essential for this event. A signi¢cant increase in
IL-1/FCS-dependent [3H]AA release caused by exogenous AA
was also observed in cPLA2-transfected cells, although this
increment was smaller than that in sPLA2-IIA-expressing cells
Fig. 1. E¡ects of exogenous AA on endogenous AA release by HEK293 transfectants. Control cells, transfectants expressing sPLA2-IIA or
cPLA2 (A), and transfectants expressing iPLA2 (B) were prelabeled with [3H]AA, and then cultured for 4 h with (solid bars) or without (open
bars) IL-1/FCS stimulation in the presence or absence of 50 WM AA. Values represent means þ S.E.M. (n = 3).
Fig. 2. E¡ects of various fatty acids and AA metabolites on endoge-
nous AA release by HEK293 transfectants. Control cells and trans-
fectants expressing sPLA2-IIA or cPLA2, prelabeled with [3H]AA,
were incubated for 4 h with IL-1/FCS in the presence of 50 WM
AA, linoleic acid (LA), oleic acid (OA) or stearic acid (SA), or with
500 ng/ml PGE2, 5-HETE or 12-HETE. Values represent means
þ S.E.M. (n = 3).
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(Fig. 1A). Basal and IL-1/FCS-mediated [3H]AA release ap-
proximately doubled after iPLA2 transfection, as reported
previously [8,9], but exogenous AA had no appreciable e¡ect
on [3H]AA release by iPLA2-expressing cells (Fig. 1B).
Assessments of fatty acid speci¢city showed that AA was
the most potent enhancer of IL-1/FCS-stimulated [3H]AA re-
lease, followed in order by linoleic acid and oleic acid, where-
as stearic acid was virtually without e¡ect (Fig. 2). sPLA2-IIA
augmented the exogenous PUFA-dependent incremental re-
lease of [3H]AA more e⁄ciently than cPLA2 under experimen-
tal conditions in which both PLA2s produced comparable
[3H]AA release in response to IL-1/FCS in the absence of
PUFAs. Enhanced [3H]AA release from parental 293 cells
was evident at concentrations of exogenous AA more than
5 WM, and sPLA2-IIA augmented release several-fold when
compared with control cells at all AA concentrations exam-
ined (Fig. 3A). In sPLA2-IIA transfectants, IL-1/FCS-stimu-
lated [3H]AA release increased to reach a plateau by 4^8 h,
whereas it continued to increase throughout the culture period
if exogenous AA was added further (Fig. 3B).
PGE2, a major AA metabolite of the COX pathway, pro-
duced no appreciable e¡ect on IL-1/FCS-induced [3H]AA re-
lease, whether or not sPLA2-IIA and cPLA2 were introduced
(Fig. 2). Moreover, the increase in [3H]AA release caused by
exogenous AA in control cells and sPLA2-IIA-expressing cells
was not appreciably suppressed by several COX inhibitors
(data not shown), implying that prostanoids are not involved
in this process. 5-HETE and 12-HETE, by-products of the
lipoxygenase pathway, also failed to augment sPLA2-IIA-
and cPLA2-mediated AA release (Fig. 2). Although we ob-
served that nordihydroguaiaretic acid, a lipoxygenase-inhibit-
ing antioxidant [16], signi¢cantly suppressed IL-1/FCS-in-
duced [3H]AA release in sPLA2-IIA-expressing cells whether
or not exogenous AA was added (Kuwata et al., unpublished
observation), it remains unclear at present whether certain
lipoxygenase metabolites (other than 5- and 12-HETEs) or
other PUFA oxidative products participate in this pathway.
3.2. Coexpression of cPLA2 and sPLA2-IIA coordinately
enhances AA release
The observation that exogenous PUFAs potently stimulate
sPLA2-IIA-mediated [3H]AA release prompted us to ask
whether the production of endogenous AA by cPLA2 would
a¡ect the function of sPLA2-IIA. To address this issue, we
employed 293 transfectants coexpressing cPLA2 and sPLA2-
IIA, and compared their AA-releasing and PGE2-producing
abilities with those of transfectants expressing each PLA2
alone. The expression of each PLA2 was veri¢ed by RNA
blotting (Fig. 4A). IL-1-dependent release of [3H]AA (Fig.
4B) and PGE2 (Fig. 4C) by cells expressing cPLA2 or
sPLA2-IIA alone was increased modestly relative to release
by control cells, as we have recently reported [8,9]. Most im-
portantly, coexpression of cPLA2 and sPLA2-IIA synergisti-
cally augmented [3H]AA release (Fig. 4B) and PGE2 produc-
tion (Fig. 4C) in IL-1-stimulated cells. [3H]AA release
preceded PGE2 generation, probably because the latter re-
quires de novo induction of COX-2, which occurs after 1^4
h of IL-1 stimulation [8].
Taking these results together, it seems reasonable to con-
sider that the AA produced endogenously by the action of
cPLA2 sensitized the cells, leading to increased sPLA2-IIA-
dependent AA release.
Fig. 4. E¡ects of cPLA2 and sPLA2-IIA coexpression on AA and
PGE2 release. A: Expression of cPLA2 and sPLA2-IIA in HEK293
transfectants as assessed by RNA blotting. [3H]AA release (B) and
PGE2 generation (C) in each transfectant after culture for the indi-
cated periods with or without IL-1. A representative result of three
independent experiments is shown.
Fig. 3. Analyses of the e¡ects of exogenous AA on sPLA2-IIA-
mediated AA release. A: AA dose response. sPLA2-expressing (solid
circles) and control (open circles) 293 cells, prelabeled with [3H]AA,
were incubated for 4 h with IL-1/FCS in the presence of the indi-
cated concentrations of AA. B: Time course. sPLA2-IIA-expressing
293 cells were cultured for the indicated periods with IL-1/FCS in
the presence (solid circles) or absence (open circles) of 50 WM AA.
A representative result of two reproducible experiments is shown.
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4. Discussion
P388The observation that AA release by sPLA2-IIA gener-
ally occurs only in agonist-stimulated cells [10] prompted us to
hypothesize that membrane rearrangement during cell activa-
tion is a crucial event leading to sPLA2-mediated membrane
phospholipid hydrolysis. In this model, the outer lea£et of the
plasma membrane of quiescent cells, rich in PC and sphingo-
myelin, is fairly resistant to the enzymatic action of sPLA2-
IIA, and cell activation perturbs the plasma membrane, loos-
ening the otherwise tightly packed membrane bilayer to be
susceptible to this enzyme. Several possible explanations
have been proposed to account for this phenomenon, among
which the roles of PUFAs in eliciting changes in membrane
structures have been demonstrated by several workers [11^15].
Balsinde et al. [14,15] have provided evidence that prior acti-
vation of cPLA2 is necessary for sPLA2 (in this case, the type
V isozyme, a close homolog of sPLA2-IIA) to exert its func-
tion in P388D1 macrophage-like cells, and that supplementing
these cells with exogenous AA restores the requirement of
cPLA2 for sPLA2 activation. Robinson et al. [13] have re-
ported that sPLA2 and cPLA2, but not iPLA2, are activated
by PUFAs in human neutrophils. Moreover, we have recently
demonstrated that sPLA2-IIA-dependent eicosanoid genera-
tion is sensitive to several cPLA2 inhibitors [6,8].
In the present study, we have shown that sPLA2-IIA-medi-
ated AA release from intact cells is markedly potentiated by
exogenous PUFAs, among which AA elicits the most potent
e¡ect. In contrast, AA release by cPLA2 was enhanced only
modestly, and release by iPLA2 was una¡ected, by exogenous
PUFAs, indicating that the augmentative e¡ect of PUFAs on
endogenous AA release by intact cells is somewhat selective
for sPLA2-IIA. Of note, this PUFA e¡ect was observed only
in cells stimulated with IL-1/FCS. A likely explanation for this
is that IL-1/FCS may initiate the signaling transduction path-
way leading to sPLA2-IIA-mediated membrane hydrolysis in
particular cellular compartments, and PUFAs or their metab-
olites may accelerate this hydrolytic process by perturbing
membrane bilayers which are attacked by sPLA2-IIA. Impor-
tantly, the striking synergism between cPLA2 and sPLA2-IIA
observed in cotransfectants supports the theory of a positive-
feedback model, in which agonist-induced release of AA by
cPLA2 promotes further stimulation of sPLA2-mediated
membrane hydrolysis and subsequent production of PGE2
via COX-2. Certain oxidative PUFA metabolites might be
involved in this membrane sensitization process, since some
oxidants have been shown to increase sPLA2-IIA-mediated
phospholipid hydrolysis in vesicles and intact cells [12,17].
This possibility is now under investigation.
A smaller but still signi¢cant increase in [3H]AA release by
PUFAs occurred in cPLA2-expressing cells. This suggests that
cPLA2-mediated membrane hydrolysis is also facilitated by
membrane perturbation caused by PUFAs. Alternatively,
the ability of PUFAs to mobilize intracellular Ca2 [18,19]
and activate several protein kinases [20] might lead to the
post-translational activation of cPLA2. Given that sPLA2 ac-
tivates cPLA2 in some cell types [21,22], a bidirectional inter-
action between sPLA2 and cPLA2 may contribute to the syn-
ergistic augmentation of the eicosanoid-biosynthetic response
seen in the cotransfectants.
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